Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Research Report 2024

Publication ID:

PB505243363

Publication Date:

May 16, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Chronic Hepatitis B Treatment Oral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Chronic Hepatitis B Treatment Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Hepatitis B Treatment Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Chronic Hepatitis B Treatment Oral Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Chronic Hepatitis B Treatment Oral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Hepatitis B Treatment Oral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Hepatitis B Treatment Oral Drugs.
The Chronic Hepatitis B Treatment Oral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Hepatitis B Treatment Oral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Hepatitis B Treatment Oral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Hepatitis B Treatment Oral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Perspective (2019-2030)
2.2 Global Chronic Hepatitis B Treatment Oral Drugs Growth Trends by Region
2.2.1 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Hepatitis B Treatment Oral Drugs Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Chronic Hepatitis B Treatment Oral Drugs Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Dynamics
2.3.1 Chronic Hepatitis B Treatment Oral Drugs Industry Trends
2.3.2 Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Drivers
2.3.3 Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Challenges
2.3.4 Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Revenue
3.1.1 Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Revenue (2019-2024)
3.1.2 Global Chronic Hepatitis B Treatment Oral Drugs Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Hepatitis B Treatment Oral Drugs Revenue
3.4 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Hepatitis B Treatment Oral Drugs Revenue in 2023
3.5 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs Head office and Area Served
3.6 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Product and Application
3.7 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Hepatitis B Treatment Oral Drugs Breakdown Data by Type
4.1 Global Chronic Hepatitis B Treatment Oral Drugs Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Chronic Hepatitis B Treatment Oral Drugs Forecasted 麻豆原创 Size by Type (2025-2030)
5 Chronic Hepatitis B Treatment Oral Drugs Breakdown Data by Application
5.1 Global Chronic Hepatitis B Treatment Oral Drugs Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Chronic Hepatitis B Treatment Oral Drugs Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size (2019-2030)
6.2 North America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2019-2024)
6.4 North America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size (2019-2030)
7.2 Europe Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2019-2024)
7.4 Europe Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size (2019-2030)
9.2 Latin America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Hepatitis B Treatment Oral Drugs Introduction
11.1.4 GSK Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Introduction
11.2.4 Bristol Myers Squibb Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Introduction
11.3.4 Gilead Sciences Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.3.5 Gilead Sciences Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Hepatitis B Treatment Oral Drugs Introduction
11.4.4 Novartis Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Hepatitis B Treatment Oral Drugs Introduction
11.5.4 Roche Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Hepatitis B Treatment Oral Drugs Introduction
11.6.4 Merck Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Company Details
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.8.4 Dawnrays Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.8.5 Dawnrays Pharmaceutical Recent Development
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Company Details
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.9.4 Hansoh Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.9.5 Hansoh Pharmaceutical Recent Development
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Company Details
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.10.4 Chia Tai-Tianqing Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Development
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Company Details
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.11.4 Qilu pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.11.5 Qilu pharmaceutical Recent Development
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Company Details
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Introduction
11.12.4 Fujian Cosunter Pharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.12.5 Fujian Cosunter Pharma Recent Development
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Company Details
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Introduction
11.13.4 Xiamen Amoytop Biotech Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.13.5 Xiamen Amoytop Biotech Recent Development
11.14 YaoPharma
11.14.1 YaoPharma Company Details
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Chronic Hepatitis B Treatment Oral Drugs Introduction
11.14.4 YaoPharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.14.5 YaoPharma Recent Development
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Company Details
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.15.4 Kelun Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.15.5 Kelun Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.